Bridging the Gaps in Lung Cancer

Pasi A. Jänne, MD, PhD, discusses key areas of debate in lung cancer management, with a focus on defining the optimal duration of adjuvant targeted therapy.

Xiuning Le, MD, PhD, discusses the current landscape of KRAS G12C inhibitors and emerging strategies for optimizing KRAS inhibition in NSCLC.

Maurice Perol, MD, discusses the persistent unmet need for effective treatments following progression on immunotherapy in NSCLC.

Solange Peters, MD, PhD, discusses the necessity of global consensus meetings to navigate clinical "gray zones" in lung cancer management.

Antonio Passaro, MD, PhD, discusses testing methodologies and clinical trials for MET, the most studied resistance biomarker, following progression on EGFR TKIs.

Corinne Faivre-Finn, MD, discusses ongoing clinical debates regarding patient selection and optimal delivery of concurrent chemoradiotherapy followed by immunotherapy in LS-SCLC.

Jacob Sands, MD, discusses ways to manage the toxicities associated with the DLL3 inhibitor tarlatamab in the treatment of patients with SCLC.

Narjust Florez, MD, discusses the publication of a consensus manuscript in Cancer on recommendations for clinical strategies for lung cancer management.

Narjust Florez, MD, discusses emerging strategies to address immune checkpoint inhibitor resistance in non–small cell lung cancer.

Narjust Florez, MD, discusses current treatment preferences in frontline IO for BRAF V600E–mutated metastatic non–small cell lung cancer.

Narjust Florez, MD, discusses treatment preferences in borderline resectable NSCLC, based on real-time polling conducted during the Bridging the Gaps in Lung Cancer 2025 meeting.

Narjust Florez, MD, discusses current treatment preferences in SCLC, based on real-time polling conducted during the Bridging the Gaps in Lung Cancer 2025 meeting.

Narjust Florez, MD, discusses current treatment preferences in SCLC, based on real-time polling conducted during the 2025 Bridging the Gaps in Lung Cancer meeting.

Triparna Sen, PhD, discusses the role of immunotherapy for the treatment of patients with small cell lung cancer.

Narjust Florez, MD discusses the importance of establishing expert consensus in the evolving lung cancer treatment landscape in 2025.

Jorge Nieva, MD, discusses matched-adjusted indirect comparison data evaluating crizotinib vs alectinib, brigatinib, and lorlatinib in ALK-positive NSCLC.

Sandip P. Patel, MD, discusses toxicities associated with the use of immunotherapy-based combination regimens in patients with advanced NSCLC.

Elaine Shum, MD, discusses questions that remain regarding the first-line treatment paradigm for patients with EGFR-mutant non–small cell lung cancer.

Jessica Donington, MD, MSCR, discusses how updated data with perioperative nivolumab in NSCLC may affect future surgical decision-making.